Tweet
Financing the Biotech Industry:
Can the Risks Be Reduced?
The Biotech Law Symposia Session I
Thursday, January 23,1997 2:30-5:00 PM
In this roundtable session, experts will discuss the dependency of the
biotech industry on venture capital, the historical experience of biotech
investment, methods of evaluating economic risks, legal considerations and
safeguards, and implications for basic and applied research.
Opening Remarks:
Richard J. Testa, Esq., Managing Partner, Testa, Hurwitz & Thibeault, LLP
Roundtable Discussion:
Dr. Jonathan Beckwith, American Cancer Society Research Professor, Harvard
Medical School
Farah H. Champsi, Managing Director, Robertson, Stephens & Co. Leslie E.
Davis, Esq., Partner, Testa, Hurwitz & Thibeault, LLP Stanley C. Erck,
President and Chief Executive Officer, Procept, Inc. Professor Joshua T.
Lerner, Harvard Business School Henry A. Termeer, President, Chairman and
Chief Executive Officer, Genzyme, Inc.
Moderator:
Dean Ronald A. Cass, Boston University School of Law
The Biotech Law Symposium is a series of 4 sessions exploring the legal and
business issues of critical importance to the biotech industry and society.
The Biotech Law Symposium is open to all interested parties. You may attend
any one or all sessions. To register, please call 617-248-7852 or e-mail
biotech@tht.com and let us know if you would like to attend. There is no
fee for attending these programs.
For more information look up http://web.bu.edu/LAW or http://www.tht.com or
call Testa, Hurwitz & Thibeault, LLP at 617-975-248-7223.
The Biotech Law Symposia Session I
Thursday, January 23,1997 2:30-5:00 PM
Boston University School of Law
Barristers Hall, First Floor
765 Commonwealth Ave.
Boston, MA 02215
Can the Risks Be Reduced?
The Biotech Law Symposia Session I
Thursday, January 23,1997 2:30-5:00 PM
In this roundtable session, experts will discuss the dependency of the
biotech industry on venture capital, the historical experience of biotech
investment, methods of evaluating economic risks, legal considerations and
safeguards, and implications for basic and applied research.
Opening Remarks:
Richard J. Testa, Esq., Managing Partner, Testa, Hurwitz & Thibeault, LLP
Roundtable Discussion:
Dr. Jonathan Beckwith, American Cancer Society Research Professor, Harvard
Medical School
Farah H. Champsi, Managing Director, Robertson, Stephens & Co. Leslie E.
Davis, Esq., Partner, Testa, Hurwitz & Thibeault, LLP Stanley C. Erck,
President and Chief Executive Officer, Procept, Inc. Professor Joshua T.
Lerner, Harvard Business School Henry A. Termeer, President, Chairman and
Chief Executive Officer, Genzyme, Inc.
Moderator:
Dean Ronald A. Cass, Boston University School of Law
The Biotech Law Symposium is a series of 4 sessions exploring the legal and
business issues of critical importance to the biotech industry and society.
The Biotech Law Symposium is open to all interested parties. You may attend
any one or all sessions. To register, please call 617-248-7852 or e-mail
biotech@tht.com and let us know if you would like to attend. There is no
fee for attending these programs.
For more information look up http://web.bu.edu/LAW or http://www.tht.com or
call Testa, Hurwitz & Thibeault, LLP at 617-975-248-7223.
The Biotech Law Symposia Session I
Thursday, January 23,1997 2:30-5:00 PM
Boston University School of Law
Barristers Hall, First Floor
765 Commonwealth Ave.
Boston, MA 02215